Trulieve Cannabis Corp., together with its subsidiaries, operates as a medical cannabis company.
$10.90-2.24%
报价 2026-11-13
市值
$1.85B
EV
$2.21B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -13.1%
$8.06$12.54
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
does not hit growth, cheap, or GARP pool
爆发潜力
2026-11-13仅 EPS 线✗ 收入线✓ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22027-12 | 0.9x | -0.19 → 0.36（扭亏） | 29.9 |
| FY+32028-12 | 0.8x | -0.19 → 0.51（扭亏） | 21.4 |
毛利率 55% · TTM 收入 $1081M · 基数 EPS -0.19（调整后）
分歧大利润率驱动一次性亏损已剔除
近 90 天分组变化：2026-11-13 → 仅 EPS 线；2026-11-10 → 未命中
电话会信号
辅助标签Q3 20262026-11-05
扩产需求加速供不应求
指引 无
信心 5
分析师 4
“We expect significant growth in Georgia and Texas, with Texas representing the largest medical cannabis opportunity in the US.”
原文引用（3）
- 扩产：capital expenditures are now expected to be approximately $105 million, up from $95 million
- 需求加速：Georgia has been growing faster, candidly, than what we initially had modeled
- 供不应求：we are adding capacity in stages into 2027 to meet growing demand in all channels
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Drug Manufacturers - Specialty & Generic| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| TRLVTrulieve Cannabis Corp. | $1.85B | -2.2% | -13.8% | 59.9% | – | 6.8x | 8.2x | |
| HCMHutchison China Ltd. | $2.64B | +0.3% | +12.2% | 17% | 145.0x | – | 234.4x | |
| RGCRegencell Bioscience Holdings Limited | $2.45B | -3.6% | – | 0% | – | – | – | |
| PRGOPerrigo Company plc | $2.25B | +0.4% | -6.0% | 30.7% | – | – | 12.9x | |
| SUPNSupernus Pharmaceuticals, Inc. | $1.73B | +1.8% | +26.8% | 85.7% | 8.0x | 3.4x | 55.3x | Cheap GARP |
| ANIPANI Pharmaceuticals, Inc. | $1.62B | +0.5% | +26.6% | 61.6% | 13.7x | 5.6x | 9.2x | Cheap GARP |
| ALVOAlvotech | $1.5B | -10.3% | +3.0% | 50.7% | – | – | – | |
| PAHCPhibro Animal Health Corporation | $1.46B | +1.4% | +5.5% | 33.2% | 13.5x | 8.6x | 67.4x | |
| PCRXPacira BioSciences, Inc. | $1.46B | -0.1% | +3.2% | 77% | 103.2x | 14.4x | 8.1x | |
| 同行中位数 | – | – | +5.5% | 41.9% | 13.7x | 7.1x | 34.1x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-06-30 Q2 2026 | 2026-03-31 Q1 2026 | 2025-12-31 Q4 2025 | 2025-09-30 Q3 2025 | 2025-06-30 Q2 2025 |
|---|---|---|---|---|---|
| Revenue | $271M | $286.8M | $293.1M | $288.2M | $302.1M |
| Gross Margin | 59.9% | 59.3% | 59.8% | 58.9% | 60.6% |
| Operating Margin | -136.7% | 12.4% | 6.6% | 14.4% | 17.3% |
| Net Income | $-406.1M | $2.4M | $-42.9M | $-26.8M | $-13.8M |
| Diluted EPS | -2.1 | 0.01 | -0.22 | -0.14 | -0.07 |
| Operating Cash Flow | $53.1M | $55.7M | $59.2M | $76.8M | $85.7M |